Mirum Pharmaceuticals gets FDA approval for Atebrioz; brelovitug Phase 3 AZURE-1 meets primary endpoint

Mirum Pharmaceuticals announced FDA approval of Atebrioz for reducing new heterotopic ossification in patients 12 and older and reported positive Phase 3 AZURE-1 topline results for brelovitug in chronic hepatitis delta.Key Highlights:Original SEC Filing: Mirum Pharmaceuticals, Inc. [ MIRM ] - 8-K…